{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:47:43Z","timestamp":1761976063528,"version":"3.41.2"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The use of bivalirudin-based anticoagulation over heparin-based anticoagulation for coronary percutaneous intervention has been debated for a long time. Multiple trials have shown promising benefits of bivalirudin over heparin therapy with the most recent addition being the BRIGHT-4 trial. We performed a meta-analysis to assess evidence from these trials, focusing on the coronary intervention of the STEMI population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This meta-analysis was performed based on PRISMA guidelines after registering in PROSPERO (CRD42023394701). Databases were searched for relevant articles published before January 2023. Pertinent data from the included studies were extracted and analyzed using RevMan v5.4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 2375 studies evaluated, 13 randomized control trials with 24 360 acute ST-elevation myocardial infarction patients were included for analysis. The bivalirudin-based anticoagulation reduced the net clinical events (OR 0.75, CI 0.61\u20130.92), major adverse cardiac or cerebral events (OR 0.85, CI 0.74\u20130.98), any bleeding (OR 0.61, CI 0.45\u20130.83), major bleeding (OR 0.54, CI 0.39\u20130.75), all-cause mortality (OR 0.79, CI 0.67\u20130.92) and cardiac mortality (OR 0.78, CI 0.65\u20130.93) significantly without increasing the risk of any stent thrombosis (OR 0.92, 95% CI 0.52\u20131.61), definite stent thrombosis (OR 1.17, 95% CI 0.62\u20132.22) and acute stent thrombosis (OR 2.06, 95% CI 0.69\u20136.09) significantly at 30 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Based on this meta-analysis, bivalirudin plus a post-PCI high-dose infusion-based anticoagulation during STEMI PCI has significant benefits over heparin therapy for cardiovascular outcomes without a significant increase in the risk of thrombotic outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001289","type":"journal-article","created":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T04:00:57Z","timestamp":1697947257000},"page":"562-579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis"],"prefix":"10.1097","volume":"34","author":[{"given":"Prakash Raj","family":"Oli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Karnali Province Hospital, Birendranagar, Nepal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhan Bahadur","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mount Sinai Hospital, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen","family":"Shtembari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mount Sinai Hospital, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Om Saibaba Memorial Hospital, Kathmandu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmi","family":"Regmi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karnali Province Hospital, Birendranagar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sait Johns Hospital, HSHS Medical Group, Springfield"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Dhungel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishanth","family":"Mattumpuram","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailash","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine, University of Illinois College of Medicine, OSF Healthcare, Peoria, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Mungee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Medicine, University of Illinois College of Medicine, OSF Healthcare, Peoria, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"R1-20250729","first-page":"2083","article-title":"Epidemiology of myocardial infarct.","volume":"54","author":"Chiche","year":"1963","journal-title":"Minerva Med"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"e026811","DOI":"10.1161\/JAHA.122.026811","article-title":"Trends and outcomes of st-segment-elevation myocardial infarction among young women in the United States.","volume":"12","author":"Abe","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of st-elevation myocardial infarction: a report of the American college of cardiology foundation\/american heart association task force on practice guidelines.","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jcin.2016.03.031","article-title":"Effect of post-primary percutaneous coronary intervention bivalirudin infusion on acute stent thrombosis meta-analysis of randomized controlled trials.","volume":"9","author":"Shah","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines.","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2011.01.038","article-title":"Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis.","volume":"57","author":"Dangas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI.","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.","volume":"313","author":"Han","year":"2015","journal-title":"JAMA"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1060028015618206","article-title":"Heparin versus bivalirudin monotherapy in the setting of primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction.","volume":"50","author":"Faulkenberg","year":"2016","journal-title":"Ann Pharmacother"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes.","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2014.10.029","article-title":"Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.","volume":"65","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/5352087","article-title":"Safety and efficacy of bivalirudin versus unfractionated heparin monotherapy in patients with CAD and DM undergoing PCI: a retrospective observational study.","volume":"2022","author":"Li","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"e7204","DOI":"10.1097\/MD.0000000000007204","article-title":"Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention.","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R18-20250729","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520947942","article-title":"Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction.","volume":"48","author":"Chen","year":"2020","journal-title":"J Int Med Res"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ihj.2015.05.010","article-title":"Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb\/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - a single center observational study.","volume":"67","author":"Kaul","year":"2015","journal-title":"Indian Heart J"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.","volume":"400","author":"Li","year":"2022","journal-title":"The Lancet"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12265-013-9537-1","article-title":"Scientific foundation and possible implications for practice of the minimizing adverse haemorrhagic events by transradial access site and systemic implementation of AngioX (MATRIX) trial.","volume":"7","author":"Valgimigli","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus Bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): An open-label, single centre, randomised controlled trial.","volume":"384","author":"Shahzad","year":"2014","journal-title":"The Lancet"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.4244\/EIJ-D-17-00307","article-title":"Bivalirudin infusion to reduce ventricular infarction: the openlabel, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study.","volume":"13","author":"Van Geuns","year":"2017","journal-title":"EuroIntervention"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"e0259148","DOI":"10.1371\/journal.pone.0259148","article-title":"Reperfusion after Fibrinolytic Therapy (RAFT): an open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention.","volume":"16","author":"Faour","year":"2021","journal-title":"PLoS One"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"e008969","DOI":"10.1161\/CIRCINTERVENTIONS.120.008969","article-title":"Bivalirudin versus heparin monotherapy in ST-segment-elevation myocardial infarction.","volume":"14","author":"James","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"R30-20250729","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221077973","article-title":"Safety of bivalirudin combined with ticagrelor in the emergency PCI in patients with acute ST-segment elevation myocardial infarction.","volume":"28","author":"Wang","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"R31-20250729","first-page":"268","article-title":"Bivalirudin or heparin in primary angioplasty performed through the transradial approach: Results from a multicentre registry.","volume":"3","author":"Sciahbasi","year":"2014","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.amjcard.2015.10.029","article-title":"Impact of bleeding and bivalirudin therapy on mortality risk in women undergoing percutaneous coronary intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials).","volume":"117","author":"Ng","year":"2016","journal-title":"Am J Cardiol"},{"key":"R33-20250729","article-title":"Use of bivalirudin for anticoagulation in interventional cardiovascular procedures.","volume":"3","author":"Ge","year":"2018","journal-title":"Cardiovasc Innov Appl"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2016.04.140","article-title":"Bivalirudin versus unfractionated heparin for percutaneous coronary intervention with radial access: a meta-analysis of randomized trials.","volume":"216","author":"Mahmoud","year":"2016","journal-title":"Int J Cardiol"},{"key":"R35-20250729","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1160\/TH14-08-0646","article-title":"Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomised clinical trials.","volume":"113","author":"Piccolo","year":"2015","journal-title":"Thromb Haemost"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.recesp.2016.01.036","article-title":"Bivalirudin versus unfractionated heparin in acute coronary syndromes: an updated meta-analysis of randomized trials.","volume":"69","author":"Verdoia","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R37-20250729","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4244\/EIJV9I1A17","article-title":"Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.","volume":"9","author":"Shelton","year":"2013","journal-title":"EuroIntervention"},{"key":"R38-20250729","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023510","article-title":"Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"e002789","DOI":"10.1161\/CIRCINTERVENTIONS.115.002789","article-title":"Factors affecting bleeding and stent thrombosis in clinical trials comparing bivalirudin with heparin during percutaneous coronary intervention.","volume":"8","author":"Bittl","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"R41-20250729","first-page":"404","article-title":"ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb\/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: the EUROMAX ST-segment resolution substudy.","volume":"6","author":"Van\u2019t Hof","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/JBM.S50595","article-title":"Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysis.","author":"Medic","year":"2013","journal-title":"J Blood Med"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:02:32Z","timestamp":1753812152000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001289","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2023,9,20]]}}}